calcium channel, voltage-dependent, gamma subunit 2 |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
bradykinin receptor, beta 2 |
CITRIC ACID |
Bradykinin B2 |
-20% |
NoneNone |
NoneNone |
View
|
bradykinin receptor B2 |
CITRIC ACID |
Bradykinin B2 |
-20% |
NoneNone |
NoneNone |
View
|
chemokine (C-C motif) receptor 4 |
S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE |
Chemokine CCR4 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 1 |
S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 1 |
S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 1 |
KETOCONAZOLE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
cathepsin G |
METHOTREXATE |
Protease, Cathepsin G |
-20% |
NoneNone |
NoneNone |
View
|
mast cell protease 9 |
METHOTREXATE |
Protease, Cathepsin G |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
epidermal growth factor receptor |
FENOFIBRATE |
Protein Tyrosine Kinase, EGF Receptor |
-20% |
NoneNone |
NoneNone |
View
|
cathepsin G |
BENZO[A]PYRENE |
Protease, Cathepsin G |
-20% |
NoneNone |
NoneNone |
View
|
mast cell protease 9 |
BENZO[A]PYRENE |
Protease, Cathepsin G |
-20% |
NoneNone |
NoneNone |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
ZAPRINAST |
Adrenergic, Norepinephrine Transporter |
-20% |
NoneNone |
NoneNone |
View
|
cholecystokinin A receptor |
BENZO[A]PYRENE |
Cholecystokinin CCKA |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 |
KETOCONAZOLE |
Cyclooxygenase COX-2 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
KETOCONAZOLE |
Cyclooxygenase COX-2 |
-20% |
NoneNone |
NoneNone |
View
|
thromboxane A synthase 1 |
METHOTREXATE |
Thromboxane Synthetase |
-20% |
NoneNone |
NoneNone |
View
|
thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
METHOTREXATE |
Thromboxane Synthetase |
-20% |
NoneNone |
NoneNone |
View
|
FMS-like tyrosine kinase 1 |
ZAPRINAST |
Vascular Endothelinal Growth Factor (VEGF) |
-20% |
NoneNone |
NoneNone |
View
|
fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) |
ZAPRINAST |
Vascular Endothelinal Growth Factor (VEGF) |
-20% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 3a |
FENOFIBRATE |
Serotonin 5-HT3 |
-20% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 3b |
FENOFIBRATE |
Serotonin 5-HT3 |
-20% |
NoneNone |
NoneNone |
View
|
cholinergic receptor, muscarinic 3 |
METHOTREXATE |
Muscarinic M3 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 3 |
DEXCHLORPHENIRAMINE |
Protein Serine/Threonine Kinase, ERK1 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 3 |
DEXCHLORPHENIRAMINE |
Protein Serine/Threonine Kinase, ERK1 |
-20% |
NoneNone |
NoneNone |
View
|
arginine vasopressin receptor 1A |
METHOTREXATE |
Vasopressin V1A |
-20% |
NoneNone |
NoneNone |
View
|
cholinergic receptor, muscarinic 2 |
FENOFIBRATE |
Muscarinic M2 |
-20% |
NoneNone |
NoneNone |
View
|
matrix metallopeptidase 9 |
CIGLITAZONE |
Protease, Matrix Metalloprotease-9 (MMP-9) |
-20% |
NoneNone |
NoneNone |
View
|
matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) |
CIGLITAZONE |
Protease, Matrix Metalloprotease-9 (MMP-9) |
-20% |
NoneNone |
NoneNone |
View
|
DNA encoding receptor of vasoactive intestinal polypeptide |
CIGLITAZONE |
Vasoactive Intestinal Peptide VIP1 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 |
CIGLITAZONE |
Cyclooxygenase COX-2 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
CIGLITAZONE |
Cyclooxygenase COX-2 |
-20% |
NoneNone |
NoneNone |
View
|
Protein-tyrosine kinase, Fyn |
CIGLITAZONE |
Protein Tyrosine Kinase, Fyn |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
ACETAZOLAMIDE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
ACETAZOLAMIDE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
synaptic vesicle glycoprotein 2b |
ERGOCORNINE |
beta-Lactamase |
-20% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 3a |
ERGOCORNINE |
Serotonin 5-HT3 |
-20% |
NoneNone |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 3b |
ERGOCORNINE |
Serotonin 5-HT3 |
-20% |
NoneNone |
NoneNone |
View
|
Cytochrom P450-2C19 monooxygenase |
Y-27632 |
CYP450-2C19 Inhibition |
-20% |
NoneNone |
NoneNone |
View
|
Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
Y-27632 |
CYP450-2C9 Inhibition |
-20% |
NoneNone |
NoneNone |
View
|
cytochrome P450, family 2, subfamily C, polypeptide 9 |
Y-27632 |
CYP450-2C9 Inhibition |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 14 |
CIGLITAZONE |
Protein Serine/Threonine Kinase, p38alpha |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
CIGLITAZONE |
Protein Serine/Threonine Kinase, p38alpha |
-20% |
NoneNone |
NoneNone |
View
|
aldo-keto reductase family 1, member B1 (aldose reductase) |
KETOCONAZOLE |
Aldose Reductase |
-20% |
NoneNone |
NoneNone |
View
|
aldo-keto reductase family 7, member A2 (aflatoxin aldehyde reductase) |
KETOCONAZOLE |
Aldose Reductase |
-20% |
NoneNone |
NoneNone |
View
|
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) |
KETOCONAZOLE |
Aldose Reductase |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 1 |
KETOCONAZOLE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
METYRAPONE |
Calcium Channel Type L, Phenylalkylamine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
TRIHEXYPHENIDYL |
Calcium Channel Type L, Dihydropyridine |
-20% |
NoneNone |
NoneNone |
View
|
tachykinin receptor 1 |
METOCLOPRAMIDE |
Tachykinin NK1 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 1 |
PIPAMAZINE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 1 |
PIPAMAZINE |
Protein Serine/Threonine Kinase, ERK2 |
-20% |
NoneNone |
NoneNone |
View
|
neuropeptide Y receptor Y2 |
TROGLITAZONE |
Neuropeptide Y2 |
-20% |
NoneNone |
NoneNone |
View
|
neuropeptide Y receptor Y2 |
TROGLITAZONE |
Neuropeptide Y2 |
-20% |
NoneNone |
NoneNone |
View
|
Protein-tyrosine kinase, Fyn |
TROGLITAZONE |
Protein Tyrosine Kinase, Fyn |
-20% |
NoneNone |
NoneNone |
View
|
nitric oxide synthase 2A (inducible, hepatocytes) |
EPIRUBICIN |
Nitric Oxide Synthase, Inducible (iNOS) |
-20% |
NoneNone |
NoneNone |
View
|
nitric oxide synthase 2, inducible |
EPIRUBICIN |
Nitric Oxide Synthase, Inducible (iNOS) |
-20% |
NoneNone |
NoneNone |
View
|
Protein-tyrosine kinase, Fyn |
KETOPROFEN |
Protein Tyrosine Kinase, Fyn |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase 5a, mitochondrial |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase 3 |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase 2 |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase 4 |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase XI |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase IX |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase VIII |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase VII |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase VA, mitochondrial |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase IV |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase III, muscle specific |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase I |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase XIV |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase VB, mitochondrial |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase XII |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase VI |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
carbonic anhydrase II |
MICONAZOLE |
Carbonic Anhydrase |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
PREDNISONE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
PREDNISONE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
mitogen activated protein kinase 14 |
PREDNISONE |
Protein Serine/Threonine Kinase, p38alpha |
-20% |
NoneNone |
NoneNone |
View
|
mitogen-activated protein kinase 14 |
PREDNISONE |
Protein Serine/Threonine Kinase, p38alpha |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel associated protein 1 |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel associated protein 2 |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type III, beta |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, alpha |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IX, alpha |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type VII, alpha |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
amiloride-sensitive cation channel 5, intestinal |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type III, beta |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type XI, alpha |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, beta |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
CIPROFIBRATE |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type II, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1 alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1 gamma |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1 beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type XI, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1, gamma |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1, delta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1 alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type X, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IX, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage gated, type VIII, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type VII, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type III, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type II, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel associated protein 1 |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel associated protein 2 |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type III, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IX, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type VII, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
amiloride-sensitive cation channel 5, intestinal |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type III, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type XI, alpha |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type I, beta |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
FOSCARNET |
Sodium Channel, Site 2 |
-20% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 5 (DBSS) |
GW-1929 |
Tumor Necrosis Factor (TNF), Non-Selective |
-20% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 1b |
GW-1929 |
Tumor Necrosis Factor (TNF), Non-Selective |
-20% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 1a |
GW-1929 |
Tumor Necrosis Factor (TNF), Non-Selective |
-20% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 4 |
GW-1929 |
Tumor Necrosis Factor (TNF), Non-Selective |
-20% |
NoneNone |
NoneNone |
View
|
tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) |
GW-1929 |
Tumor Necrosis Factor (TNF), Non-Selective |
-20% |
NoneNone |
NoneNone |
View
|
DNA encoding receptor of vasoactive intestinal polypeptide |
IDARUBICIN |
Vasoactive Intestinal Peptide VIP1 |
-20% |
NoneNone |
NoneNone |
View
|
A3 adenosine receptor |
SECOBARBITAL |
Adenosine A3 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 |
17-METHYLTESTOSTERONE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
17-METHYLTESTOSTERONE |
Cyclooxygenase COX-1 |
-20% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA1 (alpha 1) |
ZOPICLONE |
Glutamate, AMPA |
-20% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA2 |
ZOPICLONE |
Glutamate, AMPA |
-20% |
NoneNone |
NoneNone |
View
|
glutamate receptor, ionotropic, AMPA3 (alpha 3) |
ZOPICLONE |
Glutamate, AMPA |
-20% |
NoneNone |
NoneNone |
View
|
glutamate receptor subunit 4c |
ZOPICLONE |
Glutamate, AMPA |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
STANOLONE |
Calcium Channel Type L, Benzothiazepine |
-20% |
NoneNone |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
6-MERCAPTOPURINE |
Adrenergic alpha2B |
-20% |
NoneNone |
NoneNone |
View
|
3-hydroxy-3-methylglutaryl-Coenzyme A reductase |
SULFISOXAZOLE |
HMG-CoA Reductase |
-20% |
NoneNone |
NoneNone |
View
|